Author:
Li Yuyang,Tsang Julia Y.,Tam Fiona,Loong Thomson,Tse Gary M.
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference40 articles.
1. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy;Nakada;Chem Pharm Bull (Tokyo),2019
2. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer;Modi;N Engl J Med,2020
3. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer;Schettini;NPJ Breast Cancer,2021
4. HER2-Low breast cancer: pathological and clinical landscape;Tarantino;J Clin Oncol,2020
5. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials;Denkert;Lancet Oncol,2021
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献